Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia

NCT06672263 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06672263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06672263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2024
Completion date
December 31, 2026
Enrollment
120 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia